A Study of Rilvegostomig Plus Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection

Overview

About this study

The purpose of this study is to assess the effictiveness and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Histologically confirmed adenocarcinoma of the biliary tract (intrahepatic or
extrahepatic) after macroscopically complete resection (R0 or R1)

- Provision of a tumor sample collected at surgical resection.

- Randomization within 12 weeks after resection with adequate healing and removal of
drains.

- Confirmed to be disease-free by imaging within 28 days prior to randomization.

- Eastern Cooperative Oncology Group performance status of 0 or 1

Exclusion Criteria:

- Participants with locally-advanced, unresectable, or metastatic disease at initial
diagnosis.

- Ampullary cancer, neuroendocrine, mixed neuroendocrine and non-neuroendocrine
neoplasms and nonepithelial tumors.

- Any anti-cancer therapy for BTC prior to surgery

- Active or prior documented autoimmune or inflammatory disorders or any severe or
uncontrolled systemic disease

- Current or prior use of immunosuppressive medication within 14 days before the first
dose

- Thromboembolic event within 3 months

- Active HBV or HCV infection unless treated.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/1/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Rory Smoot, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Hani Babiker, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Tanios Bekaii-Saab, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available